Baxter to divest biopharma business for $4.25 billion

said on Monday a private-equity group, which includes Warburg Pincus and Advent International, has agreed to buy its biopharma solutions unit for $4.25 billion.

Baxter announced its intent to explore alternatives for its biopharma solutions business and spin off its kidney care units in January, stating the restructuring will allow greater alignment with the company's manufacturing footprint.the private-equity consortium was in the lead to acquire Baxter's biopharma solutions business.

Baxter estimates the transaction will reduce the company's earnings by about $0.10 per share in the fourth quarter.

مصر أحدث الأخبار, مصر عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Baxter to sell its BioPharma business for $4.25 billion to Advent International, Warburg Pincus as part of ‘transformation journey’Shares of Baxter International Inc. rose 1.2% in premarket trading Monday, after the health care products company announced an agreement to divest its...
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »